Curated News
By: NewsRamp Editorial Staff
July 20, 2026

VERAXA Biotech Receives Key Regulatory Advice for BiTAC-TCE Cancer Therapy

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • VERAXA Biotech's BiTAC-TCE therapy receives regulatory clarity, potentially offering a competitive edge in cancer treatment.
  • VERAXA's BiTAC-TCE platform uses dual-targeting, conditionally active mechanism to selectively kill cancer cells while sparing healthy ones.
  • VERAXA's safer cancer therapy could improve patient outcomes by reducing side effects compared to traditional T-cell engagers.
  • VERAXA's BiTAC-TCE therapy targets cancer cells expressing both markers, sparing cells with only one, a clever double-lock approach.

Impact - Why it Matters

This news matters because it signals regulatory alignment with VERAXA's novel BiTAC-TCE platform, which aims to improve cancer treatment by selectively targeting dual antigens on tumor cells while sparing healthy tissue. If successful, this could lead to therapies with fewer side effects and better outcomes for patients, addressing a critical need in oncology. Investors should watch as this regulatory clarity paves the way for clinical trials, potentially impacting the biotech landscape and offering a new approach to T-cell engagers.

Summary

VERAXA Biotech (NASDAQ: VRXA) has announced a significant regulatory milestone: it received Scientific Advice from Germany’s Paul-Ehrlich-Institute regarding its lead proprietary BiTAC-TCE cancer therapy program. The regulatory feedback provides greater clarity on the proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform. This represents an early but crucial step in advancing the program toward clinical development. The company also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026, showing that its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets while sparing cells expressing only one target. These studies demonstrated a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index.

VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. The full press release can be accessed at https://ibn.fm/jpXam.

MissionIR (MIR) is a specialized communications platform that assisted in syndicating this content. MIR is part of the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, visit www.MissionIR.com.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech Receives Key Regulatory Advice for BiTAC-TCE Cancer Therapy

blockchain registration record for this content.